BUSINESS

• Mitsubishi Tanabe to Shed 10-Plus % of Japan Workforce
  February 4, 2016

• Sumitomo Dainippon Looks to Tap New Drugs to Counter US Latuda LOE
  February 4, 2016

• Sovaldi, Harvoni Haul in Nearly US$1.9 Billion in Japan: Gilead
  February 4, 2016

• Sakigake: Now and Future (1) - Topical Sirolimus on Track for Application in 2018 for 1st-in-World Indication
  February 4, 2016

• Belsomra Most Promoted Drug for GPs for 6 Straight Month: Anterio
  February 3, 2016

• Seikagaku, Kaken Call Off Artz Development for Expanded Indication
  February 3, 2016

• Sakigake-Designated NS-065 Now in PI/II: Nippon Shinyaku
  February 3, 2016

• Eisai’s Next Mid-Term Biz Plan Will Show New Twist to Generic Operations: Exec
  February 3, 2016

• J-TEC Files Skin-Derived Cell Sheet JACE for Giant Pigmented Nevus
  February 2, 2016

• Pola Pharma to Take Over GSK’s Marketing Authorization for Acne Drug Duac
  February 2, 2016

• Eisai Gets Japan, Asia Rights to HDAC Inhibitor
  February 2, 2016

• Kyowa Kirin to Boost Overseas Biz in Next 5 Years, Japan Market Unpredictable: President
  February 2, 2016

• Astellas, Tohoku Univ. Spinoff Link Up on Gene Therapy for Retinitis Pigmentosa
  February 2, 2016

• Sanofi Files Japan NDA for Plerixafor in Response to Govt Request
  February 2, 2016

• Retooling Generic Business - 3: Eisai “Carefully Considering” Future Course; “Not a Core Field,” Mitsubishi Tanabe Says
  February 2, 2016

• Daiichi Sankyo to Continue Negotiations with FDA on Edoxaban Restriction: CEO
  February 1, 2016

• Kyowa Kirin Enjoys 87% Profit Jump in 2015
  February 1, 2016

• Kyowa Kirin to Forge Stand-Alone Sales Regime in US: 5 Year Plan
  February 1, 2016

• Retooling Generic Business - 2: Mochida Seeks to Expand Alliances for Biosimilar Candidates
  February 1, 2016

• FDA OKs Eisai’s Halaven for Liposarcoma
  February 1, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 483
• 484
• 485
• 486
• 487
• 488
• 489
• 490
• 491
• …
• Next ›
• 最終 »